Grant A. Mcarthur

Grant A. Mcarthur

Grattan St
Melbourne, VIC 3000, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 60 publications

A Framework for MRI Characterization of Intracranial Metastatic Disease.

A Framework for MRI Characterization of Intracranial Metastatic Disease.

Journal: Radiology. Imaging cancer

Published: April 03, 2026

Reply to: The chemotherapeutic drug CX-5461 is a potent mutagen in cultured human cells.

Reply to: The chemotherapeutic drug CX-5461 is a potent mutagen in cultured human cells.

Journal: medRxiv : the preprint server for health sciences

Published: November 19, 2025

Next-Generation Oncolytic Viruses to Overcome Resistance to Anti-PD-1 Therapy in Melanoma.

Next-Generation Oncolytic Viruses to Overcome Resistance to Anti-PD-1 Therapy in Melanoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 15, 2025

Current and emerging opportunities for deintensification of systemic therapies in melanoma: A scoping review.

Current and emerging opportunities for deintensification of systemic therapies in melanoma: A scoping review.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 11, 2025

CP-GEP identifies high-risk T1a melanoma patients beyond established adverse features.

CP-GEP identifies high-risk T1a melanoma patients beyond established adverse features.

Journal: Journal of the American Academy of Dermatology

Published: June 23, 2025

A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis.

A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis.

Journal: Future oncology (London, England)

Published: May 26, 2025

Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma.

Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma.

Journal: Nature communications

Published: May 21, 2025

Sensitivity to immune checkpoint inhibitors in BRAF/MEK inhibitor refractory melanoma.

Sensitivity to immune checkpoint inhibitors in BRAF/MEK inhibitor refractory melanoma.

Journal: Journal for immunotherapy of cancer

Published: April 28, 2025

Microbiota-derived butyrate promotes a FOXO1-induced stemness program and preserves CD8+ T cell immunity against melanoma.

Microbiota-derived butyrate promotes a FOXO1-induced stemness program and preserves CD8+ T cell immunity against melanoma.

Journal: Immunity

Published: March 14, 2025

Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey.

Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey.

Journal: The Lancet. Oncology

Published: October 14, 2024

Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study.

Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study.

Journal: The Lancet. Oncology

Published: September 26, 2024

Leveraging the potential for deintensification in cancer care.

Leveraging the potential for deintensification in cancer care.

Journal: Nature cancer

Published: September 20, 2024

Showing 1-12 of 60

Last Updated: 09/26/2026